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Background: Infective endocarditis (IE) is an infection involving either native or prosthetic heart valves, 
the endocardial surface of the heart or any implanted intracardiac devices. IE is a rare condition affecting 
3–15 patients per 100,000 population. In-hospital mortality rates in patients with IE remain high at around 
20% despite treatment advances. There is no consensus recommendation favoring either bioprosthetic valve 
or mechanical valve implantation in the setting of IE; patient age, co-morbidities and preferences should be 
considered selecting the replacement prosthesis.
Methods: A systematic review and meta-analysis of studies reporting the outcomes of patients undergoing 
bioprosthetic or mechanical valve replacement for infective endocarditis with data extracted for overall 
survival, valve reinfection rates and valve reoperation. 
Results: Eleven relevant studies were identified, with 2,336 patients receiving a mechanical valve 
replacement and 2,057 patients receiving a bioprosthetic valve replacement. There was no significant 
difference for overall survival between patients treated with mechanical valves and those treated with 
bioprosthetic valves [hazard ratio (HR) 0.94, 95% confidence interval (CI): 0.73–1.21, P=0.62]. There 
was no significant difference in reoperation rates between patients treated with a bioprosthetic valve and 
those treated with a mechanical valve (HR 0.82, 95% CI: 0.34–1.98, P=0.66) and there was no significant 
difference in the rate of valve reinfection rates (HR 0.95, 95% CI: 0.48–1.89, P=0.89).
Conclusions: The presence of infective endocarditis alone should not influence the decision of which type 
of valve prosthesis that should be implanted. This decision should be based on patient age, co-morbidities 
and preferences. 
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Introduction
Infective endocarditis (IE) is an infection involving either 
native or prosthetic heart valves, the endocardial surface 
of the heart or any implanted intracardiac devices (1). The 
intact endocardium is an effective barrier to infection, with 
the risk of endocarditis rising for individuals with congenital 
intracardiac defects, acquired degenerative valvular lesions 
and implanted intra-cardiac prostheses (2); however, it 
remains an important condition with significant associated 
morbidity and mortality. IE is a rare condition affecting 
3–15 patients per 100,000 population (3-5). Infective 
endocarditis is commonly diagnosed according to the 
modified Duke criteria (6) which determines the likelihood 
of a patient having IE based on organisms detected on 
blood culture, echocardiographic images and clinical 
examination. In patients with prosthetic valve replacement, 
the risk of developing prosthetic endocarditis is 2.2–3.7% 
(7-9). Aggressive surgical treatment is often required with 
surgery indicated in up to half of patients with native valve 
endocarditis (10,11). In-hospital mortality rates in patients 
with IE remain high at around 20% despite treatment 
advances (11). 
Indications for surgical intervention for left-sided 
IE are relatively well defined with urgent intervention 
suggested for patients without adequate control of sepsis 
despite appropriate antibiotics, for patients with evidence 
of intra-cardiac abscess formation or other paravalvular 
extension, for patients with heart failure secondary to 
valve destruction or fistula formation, and to prevent 
catastrophic embolic phenomena in the presence of 
large mobile vegetations (12,13). Where possible, valve 
repair is preferred over replacement, particularly for 
right-sided and mitral valve IE. There is no consensus 
recommendation for either bioprosthetic valve or 
mechanical valve in the setting of IE and patient age, 
co-morbidities and preferences should be considered in 
making the decision for valve selection (12,14).
In the general population, the European Society of 
Cardiology suggest treatment with mechanical valves 
under the age of 60 for a valve in the aortic position or 
under the age 65 for a valve in the mitral position (15). 
The American Heart Association guidelines recommend 
a mechanical valve prosthesis in patients under the age of 
50 and a bioprosthetic valve prosthesis over the age of 70. 
In between these ages, patient factors and preferences will 
determine prosthesis type (16). This meta-analysis was 
therefore undertaken to evaluate the surgical outcomes 
comparing mechanical valve replacement and bioprosthetic 
valve replacement in infective endocarditis.
Methods
Literature search strategy 
This meta-analysis was performed in accordance with 
PRISMA recommendations and guidance. The search 
strategy was employed to search electronic databases 
EMBASE, Ovid Medline, the entire Cochrane Central 
Register of Controlled Trails (CCRCT), Cochrane 
Database of Systematic reviews (CDSR), the Database 
of Abstracts of Reviews of Effects (DARE) and the ACP 
journal club from their inception to 03 March 2019. The 
search strategy included search terms for “(tissue valve OR 
bioprosthesis OR biological valve OR bioprosthetic valve 
OR xenograft OR mechanical valve) AND endocarditis”. 
The references of previous systematic reviews were assessed 
to ensure no additional publications were missed.
Selection criteria 
Eligibility for inclusion in this systematic review and meta-
analysis included papers that assessed the outcomes of 
patients undergoing conventional valve replacement with 
a bioprosthetic or mechanical valve prosthesis undertaken 
in adult patients for the treatment of infective endocarditis. 
In order to ensure sufficient center experience, papers were 
only included if more than 15 cases were reported in each 
arm. English language papers with at least 1-year follow-
up were considered for assessment. Studies were excluded if 
there was inadequate data regarding the outcomes and for 
patients treated with homograft as a bioprosthesis. If centers 
reported outcomes of overlapping patient series, then 
the most contemporary series was analyzed. Conference 
abstracts, case reports, editorials, expert opinion, reviews 
and expert opinion were excluded.
Data extraction
For the assessed papers, data was extracted from the 
reviewed text, tables and figures. Data was extracted 
independently by two of the authors (CD Flynn, NP 
Curran) and any discrepancies were reviewed and discussed 
until consensus was reached. The recorded parameters 
were: number of cases in series, procedure undertaken, 
urgency of procedure, average age, average follow-up, early 
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death, late death, valve reinfection, valve reoperation.
Statistical analysis
Meta-analysis of incidence rates of post-operative 
complications including valve reinfection, reoperation 
and overall survival. Hazard ratios were calculated from 
source Kaplan-Meier curves according to Tierney et al. 
methods (17) with mechanical valve being the reference 
group. Incidence data was assessed using Comprehensive 
Meta-analysis v3.3 (Biostat, Englewood, USA). Comparative 
outcomes were assessed using Review Manager v5.3 
(Cochrane Collaboration, Copenhagen, Denmark). Due to 
the varied patient populations, a random effects model was 
chosen for analysis. Data heterogeneity was assessed with 
the Cochrane Q statistic with P value <0.05 being significant 
and the I2 test statistic an I2 value greater than 50% 
denoting significant heterogeneity. Publication bias was 
assessed by generation of funnel plot and assessment using 
Egger’s test produced with Comprehensive Meta-analysis. 
Sensitivity analysis was performed using a “leave-one-
out” analysis. Individual patient survival data, reinfection 
and reoperation data were reconstructed using an iterative 
algorithm that was applied to digitized source Kaplan-
Meier curves and subsequently aggregated and graphed (18) 
using R (R Foundation for Statistical Computing, Vienna, 
Austria).
Results
The search strategy revealed 4,053 citations for review after 
duplications were removed with an additional two studies 
added for full text review on reviewing reference lists. After 
full review, 11 papers met the pre-determined inclusion 
criteria (19-29) (Figure S1). The included publications had 
a total analyzed patient population of 4,393 patients with 
2,336 patients receiving a mechanical valve replacement and 
2,057 patients receiving a bioprosthetic valve replacement. 
The overall study characteristics are detailed in Table 1. 
An assessment of bias was made for all studies which 
demonstrated significant risks of bias in all included studies, 
largely based on study design (Figure S2). 
The mean age of patients receiving bioprosthetic valves 
calculated from six studies reporting mean age of patients 
(19,20,22,23,28,29) was 59.2 years old (95% CI: 58.2–60.1). 
The mean age of patients receiving mechanical valves 
was 52.1 years old (95% CI: 51.4–52.9). Overall, patients 
receiving a mechanical valve were younger by 7.8 years (95% 
CI: 6.6–9.0, P<0.001). 
Ten studies reported overall survival data (19,21-29), 
drawing outcomes data from 3,884 patients (1,792 patients 
receiving bioprosthetic valves and 2,092 patients receiving 
mechanical valves). Meta-analysis of derived hazard ratio 
(HR) demonstrated no significant difference for overall 
survival between patients treated with mechanical valves 
and those treated with bioprosthetic valves (HR 0.94, 95% 
CI: 0.73–1.21; P=0.62) (Figure 1). There was significant 
heterogeneity Cochrane Q-statistic P value <0.001, I2 =75%. 
Post-hoc subgroup analysis performed to explore sources 
of heterogeneity demonstrated that analyzing outcomes 
of left sided infective endocarditis (21-23,25-29) showed 
no significant difference in overall survival, regardless of 
valve type, HR 0.97 (95% CI: 0.67–1.41, P=0.89), there was 
still significant heterogeneity in data, Cochrane q-statistic 
P=0.005, I2 =68% (Figure 1). There was a possible benefit 
for overall survival with bioprosthetic valve replacement in 
the treatment of prosthetic valve endocarditis (21,25,27) 
(HR 1.37, 95% CI: 1.01–1.85, P=0.04) (Figure 1). 
Composite survival curves demonstrated overall survival for 
bioprosthetic valves of 71.8%, 57.3%, 49.2%, and 37.5% 
at 1-, 3-, 5-, and 10-year, respectively, and 73.2%, 56.8%, 
49.3%, and 34.0% at 1-, 3-, 5-, and 10-year, respectively, 
for mechanical valves (Figure 2). Leave-one-out sensitivity 
analysis did not demonstrate any significant impact on 
overall outcomes with any one study being removed. There 
was no evidence of publication bias on visual inspection of 
a funnel plot of the standard error by log hazard ration for 
overall survival (Figure S3), nor by Egger’s test (P=0.358).
Four studies reported data on reoperation on valve 
prosthesis (22,23,25,29), drawing outcomes data from 531 
patients (302 patients receiving bioprosthetic vales and 
229 patients receiving mechanical valves). Meta-analysis 
of derived HR demonstrated no significant difference 
between reoperation rates between patients treated with 
a bioprosthetic valve and those treated with a mechanical 
valve (HR 0.82, 95% CI: 0.34–1.98, P=0.66) There was 
moderate heterogeneity with the Cochrane q statistic 
P=0.12, I2 =49% (Figure 3). Composite survival curves 
demonstrated freedom from reoperation for bioprosthetic 
valves of 90.1%, 80.7%, 79.2%, and 56.9% at 1-, 3-, 5-, and 
10-year, respectively, and 94.1%, 91.3%, 86.0%, and 75.6% 
at 1-, 3-, 5-, and 10-year, respectively, for mechanical 
valves (Figure 4). Leave-one-out sensitivity analysis did not 
demonstrate any significant difference in overall effect on 
outcomes. There was no evidence of publication bias on 
visual inspection of a funnel plot of the standard error by 
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Figure 1 Forest plot detailing survival outcomes. 
Figure 2 Composite Kaplan-Meyer curve detailing overall survival for patients receiving bioprosthetic and mechanical valve for infective 
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A
B
Figure 3 Forest plots detailing outcomes of (A) valve reoperation; (B) valve reinfection.
Figure 4 Composite Kaplan-Meyer curve detailing freedom from reoperation for patients receiving bioprosthetic and mechanical valve for 
infective endocarditis (shaded region represents 95% confidence intervals).
log hazard ration for reoperation rates (Figure S4). Egger’s 
test was not applied due to the small number of studies 
being assessed. 
Three studies reported data on valve reinfections 
(20,22,23) drawing on data from 652 patients (365 patients 
receiving bioprosthetic valves and 287 patients receiving 
mechanical valves). Meta-analysis of derived hazard ratios 
demonstrated no significant difference in the rate of valve 
reinfection rates (HR 0.95, 95% CI: 0.48–1.89; P=0.89). 
There was minimal heterogeneity in this small group of 
studies with the Cochrane Q-statistic P value of 0.35, 
I2 =5% (Figure 3B). Composite survival curves demonstrated 
a freedom from valve reinfection for bioprosthetic valves 
of 97.0%, 91.4%, 88.3%, and 79.0% at 1-, 3-, 5-, and 
10-year, respectively, and 97.1%, 93.8%, 92.3%, and 86.6% 
at 1-, 3-, 5-, and 10-year, respectively, for mechanical 
valves (Figure 5). Leave-one-out sensitivity analysis did not 
demonstrate any significant difference in overall effect on 
outcomes. There was no evidence of publication bias on 
visual inspection of a funnel plot of the standard error by 
log hazard ration for valve reinfection rates (Figure S5). 
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Figure 5 Composite Kaplan-Meyer curve detailing freedom from valve reinfection for patients receiving bioprosthetic and mechanical valve 
for infective endocarditis (shaded region represents 95% confidence intervals).
studies being assessed. 
Discussion 
The evidence supporting indications for valve selection 
in infective endocarditis is currently limited. This meta-
analysis suggests that at present there is no clear evidence 
that one prosthetic type should be selected over any 
other, which is nonetheless an important finding. There 
was significant heterogeneity when reviewing data 
from all analyses, which may relate to the varied patient 
populations being examined with variation in valve choices 
and operations. It was not possible to correct for severity 
of infective endocarditis, urgency status, concomitant 
operations or co-morbidities. An important consideration 
is that two of the three prospective studies (19,28) 
demonstrated a significant survival advantage for patients 
receiving mechanical valves, suggesting there is possibly an 
area of future research to develop more robust evidence. 
It may have been expected that bioprosthetic valves 
would have worse overall survival as this patient cohort was 
significantly older compared to those receiving mechanical 
valves. Several studies reported that increasing age was an 
independent risk factor for overall mortality in patients 
with endocarditis (19,21,27,28). Nguyen et al. (28) note that 
advancing age increased the risk for overall 5-year mortality 
in infective endocarditis (HR 1.03; CI: 1.00–1.05, P=0.037), 
which was most pronounced in the small number of patients 
who received a bioprosthetic valve under the age of 65. 
These patients had a markedly increased 5-year mortality 
compared to patients receiving a mechanical valve (HR 4.14; 
95% CI: 1.27–13.45, P=0.018). However, patients receiving 
bioprosthetic valves in that study were older overall and 
had more medical co-morbidities including liver disease 
(OR 21.86) and severe left ventricle (LV) impairment 
(OR 14.11), therefore confounding the interpretation of 
the results. Musci et al. (27) also note age at operation as 
independent risk factor for early mortality. In contrast 
to Nguyen et al., Moon et al. (26) found no difference in 
overall mortality between mechanical and bioprosthetic 
valves in patients under the age of 60. Unfortunately, there 
was insufficient data to perform adequate meta-regression 
to correct for patient age, co-morbidities or pre-operative 
status in this meta-analysis. 
The choice of valve in the general population is 
determined by balancing the risk of anticoagulation-related 
and thromboembolic complications that may be associated 
with mechanical valves versus the risk of structural valve 
degeneration and the requirement for redo valve surgery 
for patients receiving bioprosthetic valves. The cut-off for 
patients receiving a mechanical valve versus a bioprosthetic 
valve is yet to be firmly established with conflicting 
evidence regarding long-term outcomes for the two valves. 
Some evidence refutes an excess of mortality in middle-
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aged patients receiving bioprosthetic valves, including a 
large propensity-matched study of non-elderly patients. 
McClure et al. (30) demonstrated no significant difference 
in late mortality at 18 years with a cumulative survival 
estimated at 18 years of 60% for bioprosthetic valve and 
51% for mechanical valves, though not unsurprisingly they 
found an increase in the requirement for reoperation for 
bioprosthetic valves. Similarly, although Kulick et al. (31) 
demonstrated no difference in survival for patients aged 
between 50 to 65 years requiring aortic or mitral valve 
replacement, mechanical valves were associated with a 
significant increased risk of thromboembolism (HR 4.1; 
CI: 1.3–12.7, P=0.01) and an increased risk of reoperation 
associated with bioprosthetic valves (HR 7.1; CI: 1.8-27.8 
P=0.005). However, a recent meta-analysis of five studies 
by Diaz et al. (32), assessed valve replacement in patients 
between the age of 50 to 70, demonstrated a statistically 
significant reduction in long-term mortality for patients 
receiving mechanical valves (HR 0.86; 95% CI: 0.76–0.97, 
P=0.01). They did note an increased risk of major bleeding 
with mechanical valve recipients. 
There remains no simple answer for valve choice, 
particularly in middle aged patients. It appears that the 
presence of IE alone should not influence the decision 
outs ide other  pat ient  factors .  Newer-generat ion 
bioprosthetic valves with novel preservation techniques 
could optimistically reduce the rate of structural valve 
degeneration, with ongoing trials currently at 4 years follow-
up and no episodes of structural valve degeneration to 
date (33), although long-term follow-up is required to 
determine if this truly is an improvement on current 
technologies. Another addition to the decision-making 
algorithm is the ever-increasing experience with valve-
in-valve transcatheter aortic valve replacement which has 
offered equivalent mid-term survival rates with reduced 
early morbidity compared to conventional reoperative 
surgery (34-36). However, an option for valve-in-valve 
replacement is questionable for valves smaller than 21 mm, 
suggesting that expected valve size and the consequences for 
future management should play a role in prosthesis choice. 
On the other hand, the latest generation mechanical valves 
(On-x valve) have been proven to be safe with reduced doses 
of anticoagulation and have an approved target INR range of 
1.5–2.0. This reduction in anticoagulation has significantly 
reduced major and minor bleeding events without 
causing a significant increase in thromboemboli (37). 
This may address some of the major drawbacks associated 
with mechanical valve replacement.
There are several limitations that must be considered 
when interpreting results from the present review. Data 
has been collected from a relatively small number of studies 
that have been drawn from markedly different patient 
populations. Furthermore, all studies are at a high risk of 
selection bias given the non-randomized and non-blinded 
nature of the study. In particular, many studies have stark 
differences between the bioprosthetic and mechanical valve 
patient populations making accurate analysis challenging. 
Unfortunately, there is insufficient published data to 
attempt to correct for some of these differences. 
Conclusions
This meta-analysis did not identify any evidence of a 
significant survival advantage, reduction in valve reinfection 
or reoperation rate for any particular conventional 
prosthesis choice in the treatment of patients with infective 
endocarditis. It is clear that evidence guiding our decision 
making in this area is currently limited and is an area that 
would benefit from future research. The choice of prosthesis 
should continue to be made with the conscientious 
consideration to the patients age, co-morbidities and patient 
preferences. 
Expert opinion: choice of prosthetic valve in 
infective endocarditis
Zegri-Reiriz, Tauron
In patients with infective endocarditis and indication for 
surgery, the general recommendations regarding the choice 
of prosthesis (biological or mechanical) do not differ with 
respect to the general population. Both have shown similar 
rates of post-operative mortality and reinfection.
The European guidelines recommend mechanical 
prostheses for those patients under 60 years in the aortic 
position and for those under 65 years in the mitral 
position (12). According to the American Heart Association, 
mechanical prostheses are recommended in patients <50 
years and biological prostheses in <70 years (13).
However, it should be noted that these patients deserve 
some important considerations. In many cases, they have a 
serious clinical condition which is the result of uncontrolled 
infection, acute heart failure or septic embolism.
In this scenario, the risk of bleeding and the implications 
of anticoagulation in the short and medium term should 
be carefully evaluated. Thus, some young patients with a 
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high risk of bleeding could benefit from a bioprosthesis if 
carefully selected. 
In worse cases, there is a risk of severe coagulopathy, 
hepatopathy or in an embolic stroke, due to the risk of 
hemorrhagic transformation. In this population of critically 
ill patients who may need mechanical circulatory support, 
a bioprosthesis would be preferable. On the other hand, a 
sutureless bioprosthesis could be a reasonable alternative 
for surgical treatment of prosthetic aortic valve endocarditis 
with significant involvement of the aortic annulus (38).
These decisions should be individualized in each case, 
balancing the risk of bleeding due to anticoagulation against 
the possible benefit of implanting a mechanical prosthesis in 
young patients.
Expert opinion: choice of valve prosthesis in 
patients undergoing valve surgery for infective 
endocarditis
Pettersson, Coselli
In this issue of the Annals of Cardiothoracic Surgery, Flynn 
and coworkers present a systematic review and meta-
analysis comparing outcomes after surgery for left sided 
infective endocarditis (IE) using mechanical prosthesis 
versus bioprosthesis. Both choices produced very similar 
outcomes with slight trends favoring the mechanical 
valve with regard to freedom from reoperation and risk of 
recurrent endocarditis; but a possible benefit for overall 
survival with bioprosthetic valve replacement.
Current AATS Guidelines (39) for surgical treatment 
of endocarditis makes recommendations related to the 
choice of replacement valve: valve repair is preferable when 
possible. When replacement is required and the disease is 
confined to cusps, leaflets, or valve prosthesis, choice of 
replacement valve—mechanical or tissue prosthesis should 
be based on usual criteria. 
With regard to risk of recurrent endocarditis the 
guidelines say: “For patients requiring valve replacement, 
there is little evidence that risk of recurrent infection 
is different between mechanical and tissue prostheses.” 
Also, in Flynn and coworkers’ paper there is no significant 
difference in risk of recurrent endocarditis, however, in 
recent registry studies from Sweden and Denmark when 
comparing incidence of endocarditis following valve 
replacement of non-infected pathologies, bioprostheses 
were associated with higher risk of endocarditis than 
mechanical prostheses (40,41). 
The main limitation with Flynn and coworkers’ meta-
analysis is that it doesn’t take into consideration all the 
nuances, reasons for one choice over the other, information 
about the pathology and complications (e.g., stroke or 
intracranial bleed), and other factors guiding the surgeons’ 
and patients’ choice of replacement valve. It is still true 
that “Patients with IE are often very sick and have suffered 
strokes, so using allografts or bioprosthetic valves simplifies 
management and avoids postoperative anticoagulation, 
lowering the risk of hemorrhagic conversion of strokes 
and other bleeding complications.” When the disease is 
invasive and the annulus destroyed, extensive debridement, 
reconstruction and usually root replacement are required. 
In this situation many surgeons, including us believe that an 
allograft is a better choice than a prosthetic valve conduit, 
be it mechanical or bioprosthetic valve. 
F lynn  and  coworker s  shou ld  be  thanked  and 
congratulated for confirming that current guidelines 
and practices for choice of prosthetic type for patients 
with infective endocarditis are adequate and produce 





In the current issue of the Annals of Cardiothoracic Surgery, 
Flynn et al. present a systematic review and meta-analysis 
of eleven studies, published between 1989 and 2016, 
about outcomes of mechanical versus bioprosthetic valve 
substitutes in infective endocarditis (IE). The analysis did 
not identify a significant survival advantage, reduction in 
valve reinfection or reoperation with one of the valve types.
There is no clear agreement on the best prosthetic 
valve choice, neither for non-infective nor for IE. This 
is represented by different recommendations of the 
European and American guidelines (39,42). Despite 
current recommendations, mechanical valves compared 
to bioprosthetic valve substitutes are probably used in the 
ratio 1:10, with more tissue valves being implanted even 
in younger patients (43,44). Bioprostheses are increasingly 
implanted not only because anticoagulation and valve noise 
with mechanical valves remaining important aspects for 
most patients, but also because interventional options, such 
as valve-in-valve procedures in tissue valves, have become 
an attractive second step when biological valves fail (43).
Whatever guidelines recommend, neither the patient, 
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nor the surgeon can foresee, what kind of impact the choice 
of a valve (biological valve: risk of reoperation, but patient 
will “forget” about having a valve substitute in between; 
mechanical valve: valve noise and regular reminder because 
of regular anticoagulation checks) has for the patient during 
daily life.
Therefore, it remains an individual decision, which valve 
type should be used, independent of the underlying disease 
(valve surgery with/without IE). This individual decision is 
not only a patient related aspect, but also surgeon related. 
Patients with IE, especially if complicated by cerebral 
embolism, will most likely have a tissue valve, despite 
patient age. On the other hand, surgeon related factors, i.e., 
not being experienced with the use of allografts, may also 
influence the type of valve used. 
As none of the valve substitutes available for the 
treatment of IE has been shown to have a clear advantage 
over the others, surgeons should use the valve substitute 
they are most familiar and experienced with under the 
background of patient related factors.
Expert opinion: prosthetic valve endocarditis, 
still a dilemma
Antunes
In the paper published in this issue of the Annals of 
Cardiothoracic Surgery, Flynn et al. analyse the incidence 
of prosthetic valve endocarditis (PVE) in patients with 
biological and mechanical prostheses. They performed a 
meta-analysis of studies reporting the outcomes of patients 
undergoing valve replacement for infective endocarditis (IE), 
both native and prosthetic. The authors found that at 10-
year follow-up, there were no differences in overall survival, 
and freedom from valve reinfection and reoperation 
between the two types of prostheses. However, the series 
included in the study are mostly historical and include 
both native and prosthetic endocarditis, and many types of 
prostheses of both groups. 
The results are not surprising, but I cannot completely 
agree with the conclusion derived by the authors that “the 
presence of infective endocarditis alone should not influence 
the decision of which type of valve prosthesis that should 
be implanted”. Although the data is not provided by the 
authors, the fact is that there was a significant incidence of 
PVE after valve replacement in IE. There is no consensus 
with regard to favouring either bioprosthetic or mechanical 
valve implantation in the setting of IE. Hence, it is not 
a question of which of these two prostheses but if there 
are alternatives; and, in my view, there is an alternative, 
especially useful in the aortic position with significant 
disruption of the annulus—the homograft.
Several works appear to indicate that homografts 
may be more resistant to infection than either biological 
or mechanical prostheses (45,46). My own experience 
also appears to demonstrate that superiority (47). 
However, others have shown no difference in the rates of 
re-infection (23). Implantation of homografts may be 
technically more demanding and, similarly to bioprostheses, 
they have the problem of biodegradation. In any case, the 
pliability of the homograft facilitates the treatment of the 
extensively disrupted aortic annuli often seen in PVE (48). 
Some authors have also proposed the use of stentless 
xenografts for the same indications (49). Finally, the Ross 
operation has also been advocated in these situations (50), 
but it is a surgically challenging procedure to be used in an 
already complex anatomical situation.
Expert opinion: do not radically position yourself 
in the surgery for infective Endocarditis
Mestres, Quintana
In this issue of the Annals of Cardiothoracic Surgery, Flynn 
et al. used meta-analysis to understand surgical outcomes 
comparing mechanical and bioprosthetic valve replacement 
in infective endocarditis (IE). They found no significant 
difference in overall survival, reoperation and valve 
reinfection rates between patients with mechanical or 
bioprosthetic valves.
The decision of what type of valve to use in the setting 
of IE has been discussed for over sixty years since the first 
surgical replacements (51,52), and remains a challenging 
and controversial topic. In addition to considerations 
of expected anticoagulation-related events and device 
reoperations (53), IE is another factor to consider when 
choosing a prosthesis as this population has higher surgical 
risk. Current IE guidelines do not support one device over 
another due to the lack of evidence on superiority (54). 
In their analysis,  the authors found substantial 
heterogeneity in the studies and were unable to correct 
for severity of IE, urgency status, concomitant operations 
or co-morbidities. There are additional limitations in 
the Flynn et al. meta-analysis (51). It was impossible to 
separate by valve positions and type of device. It is difficult 
to understand if under the term “bioprostheses”, stentless 
597Annals of cardiothoracic surgery, Vol 8, No 6 November 2019
© Annals of Cardiothoracic Surgery. All rights reserved. Ann Cardiothorac Surg 2019;8(6):587-599 | http://dx.doi.org/10.21037/acs.2019.10.03
valves and homografts were included. Most homograft 
implants in IE correspond to the aortic position. Patients 
implanted with a homograft are at higher risk than 
those implanted with stented bioprosthesis as they have 
extravalvular spread of the infection, meaning the infection 
is more destructive, requiring extensive reconstruction, 
especially in reoperations for prosthetic valve IE (55,56). 
Considering the complexity of IE and the process of 
choosing a valve, and difficulty in producing high quality 
clinical data for this surgical population, we should 
not adopt radical positions, with or without practice 
recommendations. Guidelines are recommendations, not 
the law, and all options must be carefully individualized. 
The treating team makes considered decisions based 
on preoperative condition, comorbidities, age among 
other variables, integrating this and acting according to 
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Supplementary
Number of records excluded after full text 
review =40
• Conference abstract =12 records
• No focus on prosthesis type =7 records
• Non-comparative study =9 records
• No focus on IE =12 records
Number of full-text articles 
assessed for eligibility =70
Number of titles and 
abstracts reviewed =4055
Records identified through 
search strategy after 
duplicates removed =4,053
Additional records identified 
on bibliography review =2
Number of studies excluded 
in qualitative synthesis =11
Number of records Included 
in qualitative synthesis =30
Number of records excluded on title and 
abstract review =3985
Number of studies excluded due to 
insufficient data available for extraction =18
Number of studies excluded due to 
insufficient follow up =1
Figure S1 Study selection. PRISMA flow diagram detailing the systematic review to identify studies reporting the outcomes of bioprosthetic 
valve replacement compared to mechanical valve replacement for infective endocarditis.















































































































































































































Figure S3 Funnel plot of standard error of log hazard ratio for overall survival.
Figure S4 Funnel plot of standard error of log hazard ratio for reoperation rates. 
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